Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myelin-peptide Loaded tolDC in Multiple Sclerosis
NCT06715605Phase 2Withdrawn
- Start
- Apr 2025
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial in multiple sclerosis (MS) (2 arms). Primary endpoints: Number of new and/or enlarging T2 lesions on MRI at 18 months and Occurrence and severity of adverse events at 18 months. Planned start Apr 2025; status: withdrawn.
02
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06715605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715605.